In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

MEI Pharma, Inc.. Trade Record

NASDAQ:MEIP MEI Pharma, Inc. stock gains 18.87% Exit Jun 6, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart MEIP May 24, 2017, priceSeries
About MEI Pharma, Inc.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
86.18
Entry Date
May 24, 2017
Entry Price
1.67
Sell Date
Jun 6, 2017
Sell Price
1.99
Net Gain
18.87%
Hold Time
8 Trading Days